A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

JRCT ID: jRCT2031220301

Registered date:31/08/2022

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Solid Tumors
• Date of first enrollment: 23/09/2022
• Target sample size: 303
• Countries of recruitment: United States,Japan,Australia,Japan,Austria,Japan,Belgium,Japan,Czechia,Japan,France,Japan,Greece,Japan,Humgary,Japan,Korea,Japan,Mexico,Japan,Poland,Japan,Spain,Japan,Switzerland,Japan,Argentina,Japan,Brazil,Japan,Bulgaria,Japan,Canada,Japan,Denmark,Japan,Finland,Japan,Israel,Japan,Italy,Japan,Netherlands,Japan,Portugal,Japan,Romania,Japan,United Kingdom,Japan
• Study type: Interventional

Intervention(s)

- Experimental: Part 1: Monotherapy Dose Exploration
Participants across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease will receive 1 of 2 dose regimens of bemarituzumab to determine recommended Phase 2 dose.
Intervention: Drug: Bemarituzumab

- Experimental: Part 2: Monotherapy Dose Expansion
Participants across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease will receive the dose of bemarituzumab identified as the recommended Phase 2 dose during Part 1.
Intervention: Drug: Bemarituzumab

Outcome(s)

Primary Outcome

1. Part 1: Number of Participants Who Experience a Dose Limiting Toxicity (DLT) [ Time Frame: Day 1 to Day 28 ]
2. Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE) [ Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years) ]
Adverse events (AEs) are defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, visual acuity, and clinical laboratory tests that occur after study treatment administration will be recorded as TEAEs.
3. Part 1: Number of Participants Who Experience a Treatment-related Adverse Event [ Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years) ]
4. Part 2: Objective Response (OR) Rate [ Time Frame: Up to approximately 2 years ]
OR = complete response (CR) + partial response (PR), measured by computed tomography (CT) or magnetic resonance imaging (MRI) as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Secondary Outcome

1. Part 1: OR Rate [ Time Frame: Up to approximately 2 years ]
OR = CR + PR, measured by CT or MRI as determined by investigator per RECIST v1.1.
2. Parts 1 and 2: Disease Control (DC) Rate [ Time Frame: Up to approximately 2 years ]
DC = CR, PR, or stable disease (SD).
3. Parts 1 and 2: Duration of Response (DOR) [ Time Frame: Up to approximately 2 years ]
DOR, defined as the time from first documentation of OR (as determined by investigator per RECIST v1.1) until the first documentation of disease progression or death due to any cause, whichever occurs first. Only participants who have achieved OR will be evaluated for DOR. DOR will be censored at the last evaluable post-baseline tumor assessment prior to subsequent anticancer therapy.
4. Parts 1 and 2: Time to Response [ Time Frame: Up to approximately 2 years ]
5. Parts 1 and 2: Progression-free Survival (PFS) [ Time Frame: Up to approximately 2 years ]
PFS, defined as time from first dose of investigational product until the first documentation of radiologic disease progression or death due to any cause. PFS will be censored at the last evaluable post-baseline tumor assessment prior to subsequent therapy. Progression will be based on RECIST v1.1 (derived utilizing investigator tumor assessments).
6. Parts 1 and 2: Overall Survival (OS) [ Time Frame: Up to approximately 2 years ]
OS, defined as time from first dose of investigational product until death from any cause. Participants still alive will be censored at the date last known to be alive.
7. Part 2: Number of Participants Who Experience a TEAE [ Time Frame: Day 1 to 28 days after last dose (a maximum of 2years) ]
AEs are defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, visual acuity, and clinical laboratory tests that occur after study treatment administration will be recorded as TEAEs.
8. Part 2: Number of Participants Who Experience a Treatment-related AE [ Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years) ]
9. Parts 1 and 2: Area Under the Concentration Time Curve (AUC) of Bemarituzumab [ Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years) ]
10. Parts 1 and 2: Maximum Observed Serum Concentration (Cmax) of Bemarituzumab [ Time Frame: Day 1 to 28 days after last dose (a maximum of 2 years) ]
11. Parts 1 and 2: Observed Concentration at the End of a Dose Interval (Ctrough) of Bemarituzumab [ Time Frame: Day 1 to 28days after last dose (a maximum of 2 years) ]

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: <= 99age old
• Gender: Both

Include criteria

1. Age >= 18 years (or legal adult age within country, whichever is older) at the time that the Informed Consent Form (ICF) is signed
2. Histologically or cytologically confirmed cancer of one of the following types, refractory to or relapsed after at least 1 prior standard therapeutic regimen in the advanced/metastatic setting, as specified below. If no standard of care therapies exist for the participant, or the participant cannot tolerate or refuses standard of care anticancer therapy, the participant may be allowed to participate on the study after discussion between the investigator and Amgen medical monitor. Participants who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving bemarituzumab are available prior to consenting to participate in the trial.
- head and neck squamous cell carcinoma: >= 1 line of therapy
- triple-negative breast cancer: >= 2 lines of therapy
- Intrahepatic cholangiocarcinoma >= 1 line of therapy
- lung adenocarcinoma: at leastplatinum-based chemotherapy, checkpoint inhibitor, and targeted therapy
- platinum resistant ovarian epithelial cell carcinoma, including fallopian tube cancers and primary peritoneal cancers, defined as progression during or within 6 months of a platinum containing regimen: >= 1 line of therapy
- endometrial adenocarcinoma: >= 1 line of therapy
- cervical carcinoma: >= 1 line of therapy
- other solid tumors: >= 1 line of therapy
3. Disease that is unresectable, locally advanced, or metastatic (not amenable to curative therapy)
4. Tumor overexpresses FGFR2b as determined by centrally performed immunohistochemistry (IHC) testing
5. Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
7. Adequate organ function as determined per protocol.

Exclude criteria

1. Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.
2. Other solid tumor cohort excludes primary tumors of the CNS, squamous non-small cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma
3. Impaired cardiac function or clinically significant cardiac disease including: unstable angina within 6 months prior to first dose of study treatment, acute myocardial infarction >= 6 months prior to first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure >= 160mmHg or diastolic >= 100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, active coronary artery disease or corrected QT interval QTc >= 470
4. History of systemic disease or ophthalmologic disorders requiring chronic use of ophthalmic steroids
5. Evidence of any ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks) or actively progressing
6. Unwillingness to avoid use of contact lenses during study treatment and for at least 100 days after the end of treatment
7. Recent (within 6 months) corneal surgery or ophthalmic laser treatment or recent (within 6 months) history of, or evidence of, corneal defects, corneal ulcerations, keratitis, or keratoconus, or other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer prior/concomitant therapy
8. Prior treatment with any investigational selective inhibitor of the fibroblast growth factor (FGF)/FGF receptor pathway (unless approved standard of care for tumor indication).

Related Information

• Primary Sponsor: Kaneda Hirokazu
• Secondary ID(s): NCT05325866